597 related articles for article (PubMed ID: 36221099)
21. Cerebrospinal fluid neurofilament light chain and total-tau as biomarkers of neurodegeneration in Alzheimer's disease and frontotemporal dementia.
Giuffrè GM; Quaranta D; Costantini EM; Citro S; Martellacci N; De Ninno G; Vita MG; Guglielmi V; Rossini PM; Calabresi P; Marra C
Neurobiol Dis; 2023 Oct; 186():106267. PubMed ID: 37652185
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic and Prognostic Value of Plasma GFAP in Sporadic Creutzfeldt-Jakob Disease in the Clinical Setting of Rapidly Progressive Dementia.
Bentivenga GM; Baiardi S; Mastrangelo A; Zenesini C; Mammana A; Rossi M; Polischi B; Capellari S; Parchi P
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791145
[TBL] [Abstract][Full Text] [Related]
23. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease.
Zerr I; Villar-Piqué A; Hermann P; Schmitz M; Varges D; Ferrer I; Riggert J; Zetterberg H; Blennow K; Llorens F
Alzheimers Res Ther; 2021 Apr; 13(1):86. PubMed ID: 33883011
[TBL] [Abstract][Full Text] [Related]
25. Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.
Álvarez-Sánchez L; Peña-Bautista C; Ferré-González L; Balaguer A; Baquero M; Casanova-Estruch B; Cháfer-Pericás C
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674742
[TBL] [Abstract][Full Text] [Related]
26. Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life study.
Götze K; Vrillon A; Bouaziz-Amar E; Mouton-Liger F; Hugon J; Martinet M; Dumurgier J; Cognat E; Zetterberg H; Blennow K; Hourrègue C; Paquet C; Lilamand M
Neurobiol Dis; 2023 Jan; 176():105937. PubMed ID: 36462720
[TBL] [Abstract][Full Text] [Related]
27. Blood Neurofilament Light Chain in Different Types of Dementia.
Gu L; Shu H; Wang Y; Wang P
Curr Alzheimer Res; 2023; 20(3):149-160. PubMed ID: 37264656
[TBL] [Abstract][Full Text] [Related]
28. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
29. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
[TBL] [Abstract][Full Text] [Related]
30. Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP.
Wojdała AL; Bellomo G; Gaetani L; Toja A; Chipi E; Shan D; Chiasserini D; Parnetti L
Neurobiol Dis; 2023 Dec; 189():106356. PubMed ID: 37977432
[TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia.
Landqvist Waldö M; Frizell Santillo A; Passant U; Zetterberg H; Rosengren L; Nilsson C; Englund E
BMC Neurol; 2013 May; 13():54. PubMed ID: 23718879
[TBL] [Abstract][Full Text] [Related]
32. Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies.
Hamilton CA; O'Brien J; Heslegrave A; Laban R; Donaghy P; Durcan R; Lawley S; Barnett N; Roberts G; Firbank M; Taylor JP; Zetterberg H; Thomas A
Psychol Med; 2023 Dec; 53(16):7865-7873. PubMed ID: 37489795
[TBL] [Abstract][Full Text] [Related]
33. Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review.
Chaudhry A; Houlden H; Rizig M
J Neurol Sci; 2020 Aug; 415():116886. PubMed ID: 32428759
[TBL] [Abstract][Full Text] [Related]
34. In vivo assessment of Lewy body and beta-amyloid copathologies in idiopathic normal pressure hydrocephalus: prevalence and associations with clinical features and surgery outcome.
Giannini G; Baiardi S; Dellavalle S; Zenesini C; Cevoli S; Danner N; Jyrkkänen HK; Rossi M; Polischi B; Quadalti C; Stefanini C; Cortelli P; Milletti D; Herukka SK; Palandri G; Leinonen V; Parchi P
Fluids Barriers CNS; 2022 Sep; 19(1):71. PubMed ID: 36071460
[TBL] [Abstract][Full Text] [Related]
35. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum.
Meeter LHH; Vijverberg EG; Del Campo M; Rozemuller AJM; Donker Kaat L; de Jong FJ; van der Flier WM; Teunissen CE; van Swieten JC; Pijnenburg YAL
Neurology; 2018 Apr; 90(14):e1231-e1239. PubMed ID: 29514947
[TBL] [Abstract][Full Text] [Related]
36. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.
Toledo JB; Korff A; Shaw LM; Trojanowski JQ; Zhang J
Acta Neuropathol; 2013 Nov; 126(5):683-97. PubMed ID: 23812319
[TBL] [Abstract][Full Text] [Related]
37. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia.
Abu-Rumeileh S; Steinacker P; Polischi B; Mammana A; Bartoletti-Stella A; Oeckl P; Baiardi S; Zenesini C; Huss A; Cortelli P; Capellari S; Otto M; Parchi P
Alzheimers Res Ther; 2019 Dec; 12(1):2. PubMed ID: 31892365
[TBL] [Abstract][Full Text] [Related]
38. Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes.
Quadalti C; Calandra-Buonaura G; Baiardi S; Mastrangelo A; Rossi M; Zenesini C; Giannini G; Candelise N; Sambati L; Polischi B; Plazzi G; Capellari S; Cortelli P; Parchi P
NPJ Parkinsons Dis; 2021 Oct; 7(1):93. PubMed ID: 34635674
[TBL] [Abstract][Full Text] [Related]
39. Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers.
Cousins KAQ; Shaw LM; Chen-Plotkin A; Wolk DA; Van Deerlin VM; Lee EB; McMillan CT; Grossman M; Irwin DJ
JAMA Neurol; 2022 Nov; 79(11):1155-1164. PubMed ID: 36215050
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
